Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company dedicated to decoding biology to radically improve lives. Headquartered in Salt Lake City, Utah, the company integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize the drug discovery process.

At the core of Recursion's operations is the Recursion Operating System (OS), an AI-native, end-to-end drug discovery and development platform. This platform leverages proprietary multimodal data, purpose-built AI models, and automated wet labs to generate and analyze massive biological and chemical datasets, enabling the rapid identification of potential drug candidates. Recursion focuses on developing investigational medicines across various therapeutic areas, including oncology, rare diseases, neuroscience, immunology, inflammation, and infectious diseases, addressing significant unmet medical needs. Its pipeline includes candidates like REC-4881 for familial adenomatous polyposis and several compounds for solid tumors and B-cell malignancies.

Najat Khan assumed the role of CEO in January 2026, succeeding co-founder Chris Gibson, who transitioned to Board Chair and strategic advisor. The company is positioned as a leader in AI-driven drug discovery, aiming to accelerate the development of new medicines. Recent activities include an expanded partnership with Citeline for real-world data integration and ongoing collaborations with pharmaceutical leaders such as Roche/Genentech, Sanofi, and Bayer. Recursion is scheduled to report its first-quarter 2026 financial results on May 6, 2026.

Latest updates

Recursion Founder Steps Down, Remains Advisor Amid CEO Transition

Event summary

  • Chris Gibson, Ph.D., Founder and former Chair of Recursion Pharmaceuticals, is stepping down from the Board of Directors, concluding his term in June 2026.
  • Gibson will transition to a strategic advisor role within the company.
  • Najat Khan, Ph.D., CEO and President, took over the CEO role previously, and the company emphasizes continuity and long-term value creation.
  • Rob Hershberg, M.D., Ph.D., remains Vice-Chair of the Board and Lead Independent Director.
  • Recursion Pharmaceuticals is a publicly traded company (NASDAQ: RXRX) focused on AI-powered drug discovery.

The big picture

The departure of a founder from a board role, particularly in a high-growth TechBio company like Recursion, is a common governance evolution. While Gibson’s transition to an advisory role mitigates some disruption, it signals a move towards a more professionally managed structure. This shift occurs as the company seeks to scale its AI-driven drug discovery platform and navigate the complexities of clinical development, a process often requiring a broader range of expertise on the board.

What we're watching

Governance Dynamics
The transition of a founder from a board role often signals a shift in strategic direction, and it will be important to assess how Gibson’s continued advisory role influences Recursion’s future decisions.
Execution Risk
With a new CEO and a founder stepping back, the company’s ability to maintain momentum in its pipeline development and platform integration will be a key indicator of success.
Platform Adoption
The effectiveness of the Recursion OS in translating into therapeutic impact will be crucial; the company's ability to demonstrate tangible results from its AI-powered platform will determine investor confidence.
CID: 2374